Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma

Minarik, J.; Pika, T.; Radocha, J.; Jungova, A.; Straub, J.; Jelinek, T.; Pour,  Luděk; Pavlicek, P.; Mistrik, M.; Kubínová,  Lucie; Krhovska, P.; Machalkova, K.; Jindra, P.; Spicka, I.; Plonkova, H.; Štork,  Martin; Bacovsky, J.; Capkova, L.; Sykora, M.; Kessler, P.; Stejskal, L.; Heindorfer, A.; Ullrychova, J.; Maisnar, V.; Hajek, R.

Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	MINARIK J. PIKA T. RADOCHA J. JUNGOVA A. STRAUB J. JELINEK T. POUR Luděk PAVLICEK P. MISTRIK M. BROŽOVÁ Lucie KRHOVSKA P. MACHALKOVA K. JINDRA P. SPICKA I. PLONKOVA H. ŠTORK Martin BACOVSKY J. CAPKOVA L. SYKORA M. KESSLER P. STEJSKAL L. HEINDORFER A. ULLRYCHOVA J. MAISNAR V. HAJEK R.
Year of publication	2019
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	We have performed a face to face comparison of all-oral triplet ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice. The primary endpoint was progression free survival (PFS), secondary end points included response rates and overall survival (OS).
Related projects:	Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu